AAAAAA

   
Results: 1-19 |
Results: 19
IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: ZEDER K WALLER EK REDEI I CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD HOLDEN J HOLLAND K JONES W MCCOLLUM J MOGUL M PHILLIPS C RODEY G WINGARD JR WINTON E YEAGER AM DEVINE S
Citation: K. Zeder et al., IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cancer research, therapy & control, 5(4), 1998, pp. 221-228
PRESENCE OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS PREALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IS ASSOCIATED WITH A LOWER RELAPSE-FREE SURVIVAL (RFS)
Authors: HOLLAND HK BRAY RA OTOOLE K HOLDEN JT CONNAGHAN DG HEFFNER LT WALLER EK WINTON EF YEAGER AM
Citation: Hk. Holland et al., PRESENCE OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS PREALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IS ASSOCIATED WITH A LOWER RELAPSE-FREE SURVIVAL (RFS), Experimental hematology, 25(8), 1997, pp. 621-621
ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH MATCHED UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING A PREPARATIVE REGIMENOF HIGH-DOSE CYCLOPHOSPHAMIDE AND FRACTIONATED TOTAL-BODY IRRADIATION
Authors: GELLER RB DEVINE SM OTOOLE K PERSONS L KELLER J MAUER D HOLLAND HK DIX SP PIOTTI M REDEI I CONNAGHAN G HEFFNER LT HILLYER CD WALLER EK WINTON EF WINGARD JR
Citation: Rb. Geller et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH MATCHED UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING A PREPARATIVE REGIMENOF HIGH-DOSE CYCLOPHOSPHAMIDE AND FRACTIONATED TOTAL-BODY IRRADIATION, Bone marrow transplantation, 20(3), 1997, pp. 219-225
HIGH-DOSE CYCLOPHOSPHAMIDE, FRACTIONATED TOTAL-BODY IRRADIATION WITH INVOLVED FIELD IRRADIATION AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN MALIGNANT-LYMPHOMA
Authors: TIRONA MRBT GORDON DS CROCKER I ELEY JW YORK R HEFFNER LT WINTON EF VOGLER WR
Citation: Mrbt. Tirona et al., HIGH-DOSE CYCLOPHOSPHAMIDE, FRACTIONATED TOTAL-BODY IRRADIATION WITH INVOLVED FIELD IRRADIATION AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN MALIGNANT-LYMPHOMA, Leukemia & lymphoma, 20(3-4), 1996, pp. 249-257
MINIMAL TOXICITY AND MORTALITY IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN PLUS AUTOLOGOUS MARROW STEM-CELL TRANSPLANTATION AND COMPREHENSIVE SUPPORTIVE CARE
Authors: HOLLAND HK DIX SP GELLER RB DEVINE SM HEFFNER LT CONNAGHAN DG HILLYER CD HUGHES LL MILLER RL MOORE MR WINTON EF WINGARD JR
Citation: Hk. Holland et al., MINIMAL TOXICITY AND MORTALITY IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN PLUS AUTOLOGOUS MARROW STEM-CELL TRANSPLANTATION AND COMPREHENSIVE SUPPORTIVE CARE, Journal of clinical oncology, 14(4), 1996, pp. 1156-1164
LONG-TERM FOLLOW-UP OF EDELFOSINE PURGING FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN ACUTE-LEUKEMIA
Authors: VOGLER WR BERDEL WE WINTON EF GORDON DS GELLER RB HEFFNER LT BROCHSTEIN JA BEVERIDGE RA DALTON WS MILLER KB LAZARUS HM
Citation: Wr. Vogler et al., LONG-TERM FOLLOW-UP OF EDELFOSINE PURGING FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN ACUTE-LEUKEMIA, Experimental hematology, 24(9), 1996, pp. 615-615
ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE WITH VENOOCCLUSIVE DISEASE FOLLOWING BMT
Authors: DIX SP WINGARD JR MULLINS RE JERKUNICA I DAVIDSON TG GILMORE CE YORK RC LIN LS DEVINE SM GELLER RB HEFFNER LT HILLYER CD HOLLAND HK WINTON EF SARAL R
Citation: Sp. Dix et al., ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE WITH VENOOCCLUSIVE DISEASE FOLLOWING BMT, Bone marrow transplantation, 17(2), 1996, pp. 225-230
EVALUATION OF SUPPORTIVE CARE GUIDELINES FOR MONITORING BREAST-CANCERBONE-MARROW TRANSPLANT (BMT) PATIENTS IN THE OUTPATIENT SETTING
Authors: MIYAHARA TT DIX SP DEVINE SM HOLLAND HK CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD WALLER EK WINTON EF WINGARD JR
Citation: Tt. Miyahara et al., EVALUATION OF SUPPORTIVE CARE GUIDELINES FOR MONITORING BREAST-CANCERBONE-MARROW TRANSPLANT (BMT) PATIENTS IN THE OUTPATIENT SETTING, Blood, 86(10), 1995, pp. 838-838
TRANSPLANTATION OF HLA-IDENTICAL POSITIVELY SELECTED CD34-BLOOD (PBSC) AND MARROW (BM) FROM RELATED DONORS RESULTS IN PROMPT ENGRAFTMENT AND LOW INCIDENCE OF GVHD IN RECIPIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION( CELLS OF PERIPHERAL)
Authors: HOLLAND HK BRAY AM GELLER RB DEVINE SM MCCOLLUM J CONNAGHAN DG FLEMING WH HEFFNER LT HILLYER C WALLER EK WINTON EF WINGARD JR
Citation: Hk. Holland et al., TRANSPLANTATION OF HLA-IDENTICAL POSITIVELY SELECTED CD34-BLOOD (PBSC) AND MARROW (BM) FROM RELATED DONORS RESULTS IN PROMPT ENGRAFTMENT AND LOW INCIDENCE OF GVHD IN RECIPIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION( CELLS OF PERIPHERAL), Blood, 86(10), 1995, pp. 1543-1543
RISK-FACTORS FOR SEVERE ACUTE-RENAL-FAILURE (ARF) AFTER MATCHED UNRELATED DONOR TRANSPLANTATION (MUDT)
Authors: REDEI S GELLER RB DEVINE S OTOOLE K PERSONS L HOLLAND HK CONNAGHAN G FLEMING WH HEFFNER LT HILLYER C WALLER EK WINTON EF WINGARD JR
Citation: S. Redei et al., RISK-FACTORS FOR SEVERE ACUTE-RENAL-FAILURE (ARF) AFTER MATCHED UNRELATED DONOR TRANSPLANTATION (MUDT), Blood, 86(10), 1995, pp. 1552-1552
TACROLIMUS (FK506) COMBINED WITH METHOTREXATE (MTX) IS EFFECTIVE IN PREVENTING ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) FOLLOWING RELATED DONOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: DEVINE SM GELLER RB DIX SP CONNAGHAN DG FLEMING WH HEFFNER LT HILLYER CD HOLLAND HK WALLER EK WINTON EF WINGARD JR
Citation: Sm. Devine et al., TACROLIMUS (FK506) COMBINED WITH METHOTREXATE (MTX) IS EFFECTIVE IN PREVENTING ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) FOLLOWING RELATED DONOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 86(10), 1995, pp. 1569-1569
CRL-1336 - FIRST OF A NOVEL CLASS OF DRUGS USED TO REVERSE MULTIDRUG-RESISTANCE (MDR1) GENE-EXPRESSION IN LEUKEMIA
Authors: SHUSTER MW WEI LX SCHULMAN P KOLITZ J BUCHBINDER A ALLEN S LICHTMAN SM GELLER RB DEVINE SM HEFFNER LT MANN K
Citation: Mw. Shuster et al., CRL-1336 - FIRST OF A NOVEL CLASS OF DRUGS USED TO REVERSE MULTIDRUG-RESISTANCE (MDR1) GENE-EXPRESSION IN LEUKEMIA, Blood, 86(10), 1995, pp. 2069-2069
SIMULTANEOUS ADMINISTRATION OF INTERLEUKEN-6 (RHIL-6) AND NEUPOGEN(R)(RHG-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FORBREAST-CANCER (BCA)
Authors: DEVINE SM WINTON EF HOLLAND HK GELLER RB HEFFNER LT HILLYER CD MORRIS LE RODEY GE BEVERIDGE R LYNCH J KLEIN L DIX SP WINGARD JR
Citation: Sm. Devine et al., SIMULTANEOUS ADMINISTRATION OF INTERLEUKEN-6 (RHIL-6) AND NEUPOGEN(R)(RHG-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FORBREAST-CANCER (BCA), Blood, 84(10), 1994, pp. 10000089-10000089
INTENSIVE TIME-SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR PATIENTS (PTS) WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) OR REFRACTORY RELAPSE ACUTE-LEUKEMIA - A POTENTIAL ROLE FOR GM-CSF TO ENHANCE RECRUITMENT
Authors: GELLER RB MORRIS L WINTON EF BRAY R HEFFNER LT HOLLAND KH GILMORE C DEVINE S FARHI D JAMISON K WINGARD JR
Citation: Rb. Geller et al., INTENSIVE TIME-SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR PATIENTS (PTS) WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) OR REFRACTORY RELAPSE ACUTE-LEUKEMIA - A POTENTIAL ROLE FOR GM-CSF TO ENHANCE RECRUITMENT, Blood, 84(10), 1994, pp. 10000144-10000144
BONE-MARROW TRANSPLANTATION (BMT) FOR INDOLENT LYMPHOMA UTILIZING BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (E) FOLLOWED BY MAINTENANCE ALPHA-INTERFERON (IF) - 2-YEAR FOLLOW-UP RESULTS
Authors: HOLLAND HK HEFFNER LT GELLER RB DEVINE SM HILLYER CD WINTON EF SARAL R WINGARD JR
Citation: Hk. Holland et al., BONE-MARROW TRANSPLANTATION (BMT) FOR INDOLENT LYMPHOMA UTILIZING BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (E) FOLLOWED BY MAINTENANCE ALPHA-INTERFERON (IF) - 2-YEAR FOLLOW-UP RESULTS, Blood, 84(10), 1994, pp. 10000209-10000209
FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER MATCHED UNRELATED DONOR (MUD) MARROW TRANSPLANTATION
Authors: DEVINE SM GELLER RB HOLLAND HK MORRIS LE WINTON EF HEFFNER LT HILLYER CD RODEY GE DIX SP OTOOLE K ROUTENBERG K VOGLER WR MAUER D ARO R FITZSIMMONS WE WINGARD JR
Citation: Sm. Devine et al., FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER MATCHED UNRELATED DONOR (MUD) MARROW TRANSPLANTATION, Blood, 84(10), 1994, pp. 10000341-10000341
ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE (AUC) WITH VENOOCCLUSIVEDISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT)
Authors: DIX SP MULLINS RE JERKUNICA I DAVIDSON TG GILMORE CE YORK RC LIN LS DEVINE SM GELLER RB HEFFNER LT HILLYER CD HOLLAND HK SEAY TE VOGLER WR WINTON EF WINGARD JR SARAL R
Citation: Sp. Dix et al., ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE (AUC) WITH VENOOCCLUSIVEDISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT), Blood, 82(10), 1993, pp. 10000418-10000418
INTENSIVE TIMED SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONEAND ARA-C FOR ADULT PATIENTS WITH ACUTE-LEUKEMIA
Authors: GELLER RB SIDHU GK BRAY K GILMORE C KLEIN L ROTHFIELD C HEFFNER LT HOLLAND HK SEAY TE WINTON EF WINGARD JR SARAL R
Citation: Rb. Geller et al., INTENSIVE TIMED SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONEAND ARA-C FOR ADULT PATIENTS WITH ACUTE-LEUKEMIA, Blood, 82(10), 1993, pp. 10000538-10000538
HIGH-DOSE BUSULFAN (BU), VP-16, CYTOXAN (CY) WITH MARROW RESCUE (BMT)FOR MULTIPLE-MYELOMA (MM)
Authors: SEAY TE DEVINE SM GELLER RT HEFFNER LT HILLYER C HOLLAND HK RODEY GE SARAL R VOGLER WR WINTON EF DIX SP PASCUZZI CC YORK RC WINGARD JR
Citation: Te. Seay et al., HIGH-DOSE BUSULFAN (BU), VP-16, CYTOXAN (CY) WITH MARROW RESCUE (BMT)FOR MULTIPLE-MYELOMA (MM), Blood, 82(10), 1993, pp. 10000578-10000578
Risultati: 1-19 |